ArticleScientific reports2020
Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis: Systematic Review and Meta-Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2025Pooled it
- Nucleus-specific thalamic volumes and retinal thickness in pediatric-onset multiple sclerosis: a cross-sectional study.European journal of pediatrics · 2026Article
- Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.Annals of neurology · 2025Article
- PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.International journal of MS care · 2025Article
- Outer Retinal Layer Assessment in Patients with Relapsing-Remitting Multiple Sclerosis: Multifocal Field Electroretinography and Optical Coherence Tomography.Neuro-ophthalmology (Aeolus Press) · 2025Article
- Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Interactions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis.Annals of clinical and translational neurology · 2024Article
- Visual outcome measures in clinical trials of remyelinating drugs.BMJ neurology open · 2024Review
- Optical Coherence Tomography in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis.Biological psychiatry global open science · 2024Article
- Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis.Biomedicines · 2023Article
- Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury.IEEE reviews in biomedical engineering · 2023Review
- Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.Frontiers in neurology · 2023Review
- Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.Wiener medizinische Wochenschrift (1946) · 2022Review
- Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.Neurology · 2022Article
- Cornuside alleviates experimental autoimmune encephalomyelitis by inhibiting Th17 cell infiltration into the central nervous system.Journal of Zhejiang University. Science. B · 2021Article
- In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis.Investigative ophthalmology & visual science · 2021Article
- Applications of artificial intelligence-assisted retinal imaging in systemic diseases: A literature review.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
- Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding of the role of focal inflammation, a treatable feature, on neuro-axonal injury, is paramount to optimize neuroprotective strategy in MS. To quantify the impact of focal inflammatory activity on the rate of neuro-axonal injury over the MS course. We quantified the annualized rates of change in peripapillary retinal nerve fiber layer, ganglion cell plus inner plexiform layer (GCIPL), whole-brain, gray matter and thalamic volumes in patients with and without focal inflammatory activity in 161 patients followed over 5 years. We used mixed models including focal inflammatory activity (the presence of at least one relapse or a new/enlarging T2-FLAIR or gadolinium- enhancing lesion), and its interaction with time adjusted by age, sex, use of disease-modifying therapies and steroids, and prior optic neuritis. The increased rate of neuro-axonal injury during the first five years after onset was more prominent among active patients, as reflected by the changes in GCIPL thickness (p = 0.02), whole brain (p = 0.002) and thalamic volumes (p < 0.001). Thereafter, rates of retinal and brain changes stabilized and were similar in active and stable patients. Focal inflammatory activity is associated with neurodegeneration early in MS which reinforces the use of an early intensive anti-inflammatory therapy to prevent neurodegeneration in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.